Author:Smythe, Wynand AntonDate:2016This pharmacokinetic sub-study was nested within the phase-III OFLOTUB study investigating the shortening of tuberculosis treatment. A total of 343 adults enrolled in Benin, Guinea, Senegal, and South Africa were randomized to receive rifampicin, ...Read more
Author:Bienczak, Andrzej MarekDate:2017Efavirenz and nevirapine are the most widely used agents for treatment of HIV in children. Sources of variability in their pharmacokinetics and its association with virological outcome and adverse events in African children are poorly ...Read more
Author:Gausi, KamunkhwalaDate: 2022The global scale-up of tuberculosis treatment administered with antiretroviral therapy (ART) is the primary contributor to the 11 million averted deaths among individuals living with HIV observed between 2000 and 2019 in adults and children. ...Read more
Author:Abdelwahab, Mahmoud TareqDate: 2021Tuberculosis continues to claim millions of lives each year despite enormous efforts to control the epidemic over the past century. It remains the leading cause of death worldwide from a curable infectious disease. Tuberculosis is a significant ...Read more
Author:Tikiso, TjokoselaDate: 2021The epidemiology of HIV and TB are overlapping, particularly in sub-Saharan Africa, and TB infection remains common in HIV-positive children. The combined administration of anti-tubercular and antiretroviral therapies(ART) may lead to drug-drug ...Read more
Author:Chirehwa, Maxwell TawandaDate:2018The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in TB/HIV coinfected patients recruited in two phase III clinical trials (61 patients in TB-HAART and 222 patients in RAFA study) were described using nonlinear ...Read more